Skip to content

Study · Randomized controlled trial · n = 62 · 1993

11 results

Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations.

Cohn L, Feller AG, Draper MW, Rudman IW, Rudman D

Clinical endocrinology1 Oct 1993Cited by 73 (Europe PMC)

PMID8287568 (opens in a new tab)DOI10.1111/j.1365-2265.1993.tb02388.x (opens in a new tab)PepBankPUB-08287568
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In elderly men, 27 hGH-group participants versus two controls withdrew after baseline, mostly for reasons probably unrelated to hGH.

    In plain wordsIn elderly men, more participants withdrew from the hGH group than untreated controls, mostly for reasons probably unrelated to hGH.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseStudy dropouts after baseline
    Study

    n: not reported in source

    Comparator
    Untreated controls
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Dropouts
    27 participants
    hGH group
    Dropouts
    2 participants
    untreated group

    Source sentences

    Summary
    In total there were 27 dropouts from group I and two dropouts from group II after the six-month point, for a variety of medical and non-medical reasons, the majority probably not related to hGH therapy.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  2. 02HumanNon-randomized trialSafety outcome

    In elderly men with low IGF-I receiving hGH, 10 carpal tunnel syndrome cases could have been related to therapy.

    In plain wordsIn elderly men receiving hGH, carpal tunnel syndrome occurred and could have been related to treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableCarpal tunnel syndrome
    Study

    n = 62

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Carpal tunnel syndrome
    10 cases
    hGH-treated group

    Source sentences

    Summary
    In those who received drug (group I), there were a number of adverse reactions which could have been related to the hGH therapy: carpal tunnel syndrome 10, gynaecomastia 4, and hyperglycaemia 3.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  3. 03HumanNon-randomized trialSafety outcome

    In elderly men with low IGF-I receiving hGH, 4 gynaecomastia cases could have been related to therapy.

    In plain wordsIn elderly men receiving hGH, breast enlargement occurred and could have been related to treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableGynaecomastia
    Study

    n = 62

    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Gynaecomastia
    4 cases
    hGH-treated group

    Source sentences

    Summary
    In those who received drug (group I), there were a number of adverse reactions which could have been related to the hGH therapy: carpal tunnel syndrome 10, gynaecomastia 4, and hyperglycaemia 3.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  4. 04HumanNon-randomized trialSafety outcome

    In elderly men with low IGF-I receiving hGH, 3 hyperglycaemia cases could have been related to therapy.

    In plain wordsIn elderly men receiving hGH, high blood sugar occurred and could have been related to treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableHyperglycaemia
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Hyperglycaemia
    3 cases
    hGH-treated group

    Source sentences

    Summary
    In those who received drug (group I), there were a number of adverse reactions which could have been related to the hGH therapy: carpal tunnel syndrome 10, gynaecomastia 4, and hyperglycaemia 3.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  5. 05HumanNon-randomized trialEfficacy outcome

    In elderly men with low IGF-I, hGH increased plasma IGF-I from 0.10-0.35 to 0.5-2.2 units/ml.

    In plain wordsIn elderly men with low IGF-I, plasma IGF-I increased during hGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePlasma IGF-I range
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    IGF-I
    0.1 to 0.35 units/ml
    before hGH
    IGF-I
    0.5 to 2.2 units/ml
    during hGH

    Source sentences

    Summary
    During the hGH treatment of group I, plasma IGF-I increased from the range 0.10-0.35 units/ml into the range 0.5-2.2 units/ml.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  6. 06HumanNon-randomized trialEfficacy outcome

    In elderly men with low IGF-I, hGH increased lean body mass to 106% of initial baseline after 12 months.

    In plain wordsIn elderly men with low IGF-I, lean body mass increased during hGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass
    Study

    n: not reported in source

    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Lean body mass
    106 % of baseline
    after 12 months

    Source sentences

    Summary
    Twelve months of hGH treatment (group I) caused an increase in lean body mass to 106% of the initial baseline (month one of the protocol), and a reduction in adipose mass to 84% of the baseline.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  7. 07HumanNon-randomized trialEfficacy outcome

    In elderly men with low IGF-I, hGH reduced adipose mass to 84% of initial baseline after 12 months.

    In plain wordsIn elderly men with low IGF-I, fat mass decreased during hGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseAdipose mass
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Adipose mass
    84 % of baseline
    after 12 months

    Source sentences

    Summary
    Twelve months of hGH treatment (group I) caused an increase in lean body mass to 106% of the initial baseline (month one of the protocol), and a reduction in adipose mass to 84% of the baseline.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  8. 08HumanObservational studySafety outcome

    In elderly men receiving hGH, mean IGF-I was higher in 13 men with carpal tunnel syndrome or gynaecomastia than in 18 without presumed side-effects.

    In plain wordsIn elderly men receiving hGH, mean IGF-I was higher with carpal tunnel syndrome or breast enlargement than without presumed side-effects.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseMean IGF-I and presumed adverse effects
    Study

    n = 31

    Comparator
    18 treated men without the three presumed hGH side-effects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Among the 18 men who completed 12 months of hGH treatment without experiencing one of the three above-noted presumed hGH side-effects, mean and peak plasma IGF-I during treatment were significantly lower than among the 13 men who experienced carpal tunnel syndrome or gynaecomastia (one subject had both) while on hGH.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  9. 09HumanObservational studySafety outcome

    In elderly men receiving hGH, peak IGF-I was higher in 13 men with carpal tunnel syndrome or gynaecomastia than in 18 without presumed side-effects.

    In plain wordsIn elderly men receiving hGH, peak IGF-I was higher with carpal tunnel syndrome or breast enlargement than without presumed side-effects.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePeak IGF-I and presumed adverse effects
    Study

    n = 31

    Comparator
    18 treated men without the three presumed hGH side-effects
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Among the 18 men who completed 12 months of hGH treatment without experiencing one of the three above-noted presumed hGH side-effects, mean and peak plasma IGF-I during treatment were significantly lower than among the 13 men who experienced carpal tunnel syndrome or gynaecomastia (one subject had both) while on hGH.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  10. 10HumanObservational studySafety outcome

    In elderly men receiving hGH, carpal tunnel syndrome or gynaecomastia occurred with one exception only when mean IGF-I reached at least 1.0 units/ml.

    In plain wordsIn elderly men receiving hGH, carpal tunnel syndrome or breast enlargement rarely occurred below the reported mean IGF-I threshold.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableAdverse effects below mean IGF-I threshold
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean IGF-I threshold
    < 1 units/ml
    individuals without carpal tunnel syndrome or gynaecomastia, with one exception

    Source sentences

    Summary
    With one exception, neither carpal tunnel syndrome nor gynaecomastia occurred in any individual with a mean IGF-I level less than 1.0 units/ml during hGH treatment.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).
  11. 11HumanObservational studyEfficacy outcome

    In elderly men receiving hGH, body composition responses were larger with mean IGF-I of 0.5-1.0 than 1.0-1.5 units/ml.

    In plain wordsIn elderly men receiving hGH, body composition changed more in the lower reported IGF-I range than the higher range.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseBody composition response by IGF-I level
    Study

    n: not reported in source

    Comparator
    Mean intra-treatment IGF-I 1.0-1.5 units/ml
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The body composition responses after 12 months of treatment in group I were larger in the men whose mean intra-treatment IGF-I level was 0.5-1.0 units/ml, than in the men whose mean intra-treatment IGF-I level was 1.0-1.5 units/ml.
    3 context sentences
    Summary · context
    The subjects were then randomized into two groups so that during months 7-18, men in group I received hGH, and men in group II served as untreated controls.
    Summary · context
    Eighty-three overtly healthy elderly men, who were selected because their plasma IGF-I level was less than 0.35 units/ml.
    Summary · context
    The men were randomly assigned in a ratio of three to one into group I (n = 62) or into group II (n = 21).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.